Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
![]()
We offer a physiological, artificial heart which is a viable alternative to a human heart
Share this Article:
Tweet
|
Company
Carmat
Headquarters
Vélizy-Villacoublay, France
Management
Stephane Piat, CEO
Description
Carmat’s bioprosthetic self-regulated artificial heart is a ground-breaking innovation. This medical marvel is an amalgamation of mechanics from the aerospace industry, electronics from missile systems, and the knowledge of biologics. The incorporation of biologics makes Carmat’s artificial heart the only device made of biocompatible materials to reduce thromboembolic risks. It also uses volumetric pumps that move the actuator fluid from a flexible external bag, activating the hybrid membranes and allowing blood to enter and exit the chambers
I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info